A 17% increase of Lipoprotein
Binding of LDL to its target tissue occurs through an interaction between the LDL receptor and apolipoprotein B-100 on the LDL particle.
lipoprotein | Low-density lipoprotein | lipoprotein-associated phospholipase A2 | High-density lipoprotein | low-density lipoprotein | Lipoprotein lipase deficiency | Lipoprotein-associated phospholipase A2 |
In liver dysfunction, apolipoprotein A-II deficient lipoprotein accumulates in plasma causing increased cholesterol in RBCs.
Apolipoprotein, a lipid-binding protein that is a constituent of the plasma lipoprotein.
LRP5 (low-density lipoprotein receptor-related protein 5) acts as a co-receptor for the Wnt-family of glycoproteins which regulate bone mass.
In partnership with Abraham Kornzweig, Bassen identified Bassen-Kornzweig disease, a rare autosomal recessive disorder in which the body fails to produce chylomicrons, a low density lipoprotein (LDL) and very low density lipoprotein (VLDL).
A third, morphologically identical species, Trypanosoma brucei brucei, infects domestic and wild animals but does not cause disease in humans because it is lysed by apolipoproetin L1 in the high-density lipoprotein fraction of human serum.
Lecithin—cholesterol acyltransferase (LCAT, also called phosphatidylcholine-sterol O-acyltransferase) is an enzyme that converts free cholesterol into cholesteryl ester (a more hydrophobic form of cholesterol), which is then sequestered into the core of a lipoprotein particle, eventually making the newly synthesized HDL spherical and forcing the reaction to become unidirectional since the particles are removed from the surface.
The enzymes within this family are lipoprotein-associated phospholipase A2, cytoplasmic platelet-activating factor acetylhydrolase 2, and platelet-activating factor acetylhydrolase 1b.
The lipoprotein enhanced the ability of HDL, or “good” cholesterol to usher fat out of the arteries and into the liver for excretion leading to the purchase of Esperion Therapeutics, the tiny company that had produced recombinant Apo-A1 Milano, by Pfizer for $1.3 billion.